Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion
OTCMKTS:GNMSF

Genmab A/S Earnings Date & Estimates

Genmab A/S logo
$388.52 +10.52 (+2.78%)
As of 10/20/2026 12:23 PM Eastern

Genmab A/S is estimated to report earnings on Thursday, November 5, 2026, after market closes.

Research:ProfileEarnings History

Upcoming Earnings Announcement

Announcement Date
Time
After Market Closes
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Genmab A/S

Genmab A/S is expected to post earnings of $3.53 per share on revenue of $1.20 billion. In the same quarter a year earlier Genmab A/S reported $6.46 per share on revenue of $1.02 billion. Genmab A/S last reported on February 17, 2026, posting $0.55 per share and missing the $3.10 consensus estimate. Genmab A/S has beaten the consensus EPS estimate in 4 of its last 5 quarters.

Consensus Estimates

Consensus EPS
$3.53
Expected Revenue
$1.20 billion
Prior-Year EPS
$6.46
Prior-Year Revenue
$1.02 billion
Expected EPS Growth
-45.4%
Expected Revenue Growth
+17.5%

Recent Track Record

Last Reported
Q4 2025
Last Quarter EPS
$0.55 (Missed by -$2.55)
Last Quarter Revenue
$1.06 billion
EPS Beat Rate
4 of last 5 quarters

Prepare for the Earnings Call

Genmab A/S Earnings FAQ

Genmab A/S (OTCMKTS:GNMSF) is estimated to report earnings on Thursday, November 5, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Genmab A/S to post earnings of $3.53 per share for the quarter.

The consensus revenue estimate for Genmab A/S is $1.20 billion for the quarter.

Genmab A/S Earnings Headlines

Genmab Grants Restricted Stock Units to Board After Extraordinary General Meeting
October 7, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/genmab-grants-restricted-stock-units-to-board-after-extraordinary-general-meeting?utm_source=marketbeat.com&utm_medium=referral
GMAB jumps as Genmab posts positive Phase 3 lymphoma data
October 5, 2026  |  quiverquant.comQ
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.tc pixel
 |  Banyan Hill Publishing (Ad)
Genmab Discloses Darwin Global as 5.11% Major Shareholder
October 2, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/genmab-discloses-darwin-global-as-5-11-major-shareholder?utm_source=marketbeat.com&utm_medium=referral
Major Shareholder Announcement
October 2, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/major-shareholder-announcement-1036594362
Genmab Updates Articles of Association, Preserves Broad Capital-Raising Powers
September 9, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/genmab-updates-articles-of-association-preserves-broad-capital-raising-powers?utm_source=marketbeat.com&utm_medium=referral
See More Genmab A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Genmab A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genmab A/S and other key companies, straight to your email.

About Genmab A/S

Genmab A/S (OTCMKTS:GNMSF) is a Denmark-based biotechnology company focused on discovering, developing and commercializing antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary technologies to create differentiated antibodies and antibody-drug conjugates designed to engage the immune system or target specific disease-related proteins.

Genmab’s technologies include the DuoBody platform for generating bispecific antibodies, as well as the HexaBody platform for developing antibodies with enhanced activity. Its research and development activities cover hematologic cancers, solid tumors and selected immunological conditions. Genmab also develops therapies independently and through collaborations with pharmaceutical companies.

The company’s partnered products include DARZALEX (daratumumab) for multiple myeloma, Kesimpta (ofatumumab) for multiple sclerosis, and Tivdak (tisotumab vedotin) for cervical cancer. Genmab and AbbVie are also developing and commercializing EPKINLY, known as TEPKINLY in some markets, an immunotherapy for certain types of B-cell lymphoma. Product availability and regulatory approvals vary by geography.

Founded in 1999, Genmab is headquartered in Copenhagen and serves international markets through its global development, commercial and partnership activities. The company is led by Chief Executive Officer Jan van de Winkel, who has been associated with Genmab since its early development and has guided its transition into a commercial-stage biotechnology business.

View Genmab A/S Profile
Earnings Tools